Paper Details

  1. Home
  2. Paper Details

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials.

Author: DicembriniI, MannucciE, MonamiM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This meta-analysis aimed to evaluate the risk of pancreatitis associated with Dipeptidyl Peptidase-4 inhibitors (DPP4i) by systematically collecting information from randomized clinical trials.
Paper Details　
Original Abstract of the Article :
Some observational studies reporting an increased risk of pancreatitis in association with Dipeptidyl Peptidase-4 inhibitors (DPP4i) have raised concerns on the overall safety of this class. Aim of the present meta-analysis is the systematic collection of information on pancreatitis in randomized cl...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/dom.12176

データ提供：米国国立医学図書館（NLM）

Dipeptidyl Peptidase-4 Inhibitors: A Look at Pancreatitis Risk

The world of pharmaceuticals is always scrutinizing the safety and effectiveness of medications. This study investigated the potential association between dipeptidyl peptidase-4 inhibitors (DPP4i), a class of medications used to treat type 2 diabetes, and the risk of pancreatitis. The researchers used a meta-analysis, like combining the wisdom of different oracles, to analyze data from multiple clinical trials.

The study found no significant increase in the risk of pancreatitis associated with the use of DPP4i. The findings suggest that DPP4i are generally safe for use in individuals with type 2 diabetes.

DPP4i: A Safe Option for Type 2 Diabetes

The findings suggest that DPP4i are generally safe for use in individuals with type 2 diabetes. The meta-analysis provides reassurance about the safety profile of this class of medications.

Understanding Drug Safety

This research highlights the importance of carefully evaluating the safety of medications. It underscores the need for rigorous research to ensure that medications are safe and effective for patients.

Dr.Camel's Conclusion

This meta-analysis provides valuable insight into the safety of DPP4i for treating type 2 diabetes. It is a reminder that responsible use of medications is essential for achieving optimal health outcomes.

Date :
  1. Date Completed 2014-10-28
  2. Date Revised 2013-12-17
Further Info :

Pubmed ID

23837679

DOI: Digital Object Identifier

10.1111/dom.12176

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.